Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.39 |
| ▸ | FABP7 | O15540 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.35 |
| ▸ | MDM4 | O15151 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8037760 | 0.88 | KMT2A (0.42) | KMT2AEPHX2FABP5FABP7CA1 | |
| SCHEMBL27960451 | 0.85 | KMT2A (0.47) | KMT2AEPHX2FABP5FABP7CA1 | |
| SCHEMBL20184843 | 0.85 | KMT2A (0.47) | KMT2AEPHX2FABP5FABP7CA1 | |
| SCHEMBL29823764 | 0.85 | KMT2A (0.43) | KMT2AEPHX2FABP5FABP7CA1 | |
| SCHEMBL30341743 | 0.82 | KMT2A (0.49) | KMT2AEPHX2FABP5FABP7CA1 | |
| SCHEMBL598210 | 0.80 | KMT2A (0.43) | KMT2AEPHX2FABP5FABP7CA1 | |
| SCHEMBL29823703 | 0.78 | KMT2A (0.40) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL28857903 | 0.78 | KMT2A (0.50) | KMT2AEPHX2FABP5FABP7CA1 | |
| SCHEMBL25660797 | 0.77 | KMT2A (0.46) | KMT2AEPHX2FABP5FABP7CA1 | |
| SCHEMBL8380006 | 0.77 | KMT2A (0.42) | KMT2AEPHX2FABP5FABP7CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1872800-B1 | Radiolabeled peptide compositions for site-specific targeting | MALLINCKRODT LLC (US) | 2012-10-17 | — | — | EP | disclosed |
| EP-1085090-B1 | IgA NEPHROPATHY-ASSOCIATED DNA | UNIV NIHON (JP) | 2011-12-14 | — | — | EP | disclosed |
| US-7858091-B2 | Antibodies to insulin-like growth factor binding protein and uses thereof | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-12-28 | — | — | US | disclosed |
| EP-2077275-A2 | IgA nephropathy-related DNA | Nihon University (JP) | 2009-07-08 | — | — | EP | disclosed |
| US-20080241960-A1 | INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-10-02 | — | — | US | disclosed |
| EP-1975175-A2 | IgA nephropathy-related DNA | Nihon University (JP) | 2008-10-01 | — | — | EP | disclosed |
| EP-0831938-B1 | RADIOLABELED PEPTIDE COMPOSITIONS FOR SITE-SPECIFIC TARGETING | MALLINCKRODT INC (US) | 2008-05-21 | — | — | EP | disclosed |
| US-7332301-B2 | Insulin-like growth factor binding protein | KYOWA HAAKKO KOGYO CO. LTD. (JP) | 2008-02-19 | — | — | US | disclosed |
| EP-1872800-A2 | Radiolabeled peptide compositions for site-specific targeting | MALLINCKRODT, INC. (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20060216739-A1 | Insulin-like growth factor binding protein | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-09-28 | — | — | US | disclosed |
| US-6194195-B1 | PURE CULTURE; FOR PRODUCTION OF HYPOTENSIVE AGENTS AND THERAPIES FOR ASTHMA, CEREBRAL APOPLEXY, ANGINA PECTORIS, ACUTE RENAL FAILURE, CARDIAC INFARCTION, AND CEREBRAL VASOSPASM | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-02-27 | — | — | US | disclosed |
| EP-0963999-A1 | E2F ACTIVITY INHIBITORY COMPOUNDS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1999-12-15 | — | — | EP | disclosed |
| EP-0922710-A1 | PEPTIDES PROMOTING THE ACTIVATION OF LATENT TGF-$g(b) AND METHOD FOR SCREENING TGF-$g(b) ACTIVITY REGULATORS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1999-06-16 | — | — | EP | disclosed |
| US-5830431-A | SOMATOSTATIN OR DERIVATIVES COUPLED TO RADIONUCLIDE BY CHELATING AGENT | MALLINCKRODT MEDICAL, INC. (US) | 1998-11-03 | — | — | US | disclosed |
| US-5804157-A | SOMATOSTATIN WITH UNMODIFIED CARBOXY TERMINAL AMINO ACID;DIAGNOSTIC OR THERAPUTIC USE FOR TARGETING BIOLOGICAL SITE; | MALLINCKRODT MEDICAL, INC. (US) | 1998-09-08 | — | — | US | disclosed |
| EP-0831938-A1 | RADIOLABELED PEPTIDE COMPOSITIONS FOR SITE-SPECIFIC TARGETING | MALLINCKRODT MEDICAL, INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| EP-0770623-A1 | NOVEL CALCITONIN DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1997-05-02 | — | — | EP | disclosed |
| WO-1996040291-A1 | RADIOLABELED PEPTIDE COMPOSITIONS FOR SITE-SPECIFIC TARGETING | MALLINCKRODT MEDICAL, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0679658-A1 | ENDOTHELIN-ANTAGONIZING PEPTIDE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1995-11-02 | — | — | EP | disclosed |
| EP-0672680-A1 | NOVEL PEPTIDE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1995-09-20 | — | — | EP | disclosed |